Paper36453028
Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition.
Paternot S and 17 others. Mol Oncol, 2024. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition. Papers, record 36453028. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36453028
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Mesothelioma, Malignant | Major topic |
| Mesothelioma | Major topic |
| Pleural Neoplasms | Major topic |
| Humans | |
| Phosphorylation | |
| Cell Proliferation | |
| Cell Line, Tumor | |
| Cyclin-Dependent Kinase 4 |
Source PubMed
Grants21
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Academic Medical Interdisciplinary Research (AMIR) Foundation (ASBL) | PubMed | |||
| ARSMESO44 | PubMed | |||
| Belgian National Cancer Plan | PubMed | |||
| Cancéropôle Ile-de-France | PubMed | |||
| Chancellerie des Universités de Paris | PubMed | |||
| Fondation pour la Recherche Médicale | PubMed | |||
| J.0002.16 | Fonds De La Recherche Scientifique - FNRS | PubMed | ||
| J.0141.19 | Fonds De La Recherche Scientifique - FNRS | PubMed | ||
| J.0169.22 | Fonds De La Recherche Scientifique - FNRS | PubMed | ||
| 7.4589.17 | Fonds De La Recherche Scientifique - FNRS | PubMed | ||
| H2020 Marie Skłodowska-Curie Actions | PubMed | |||
| Innoviris | PubMed | |||
| Institut National de la Santé et de la Recherche Médicale | PubMed | |||
| Institut National Du Cancer | PubMed | |||
| Koning Boudewijnstichting | PubMed | |||
| Ligue Contre le Cancer | PubMed | |||
| National Health Institute | PubMed | |||
| 2014-130 | Stichting Tegen Kanker | PubMed | ||
| 2018-138 | Stichting Tegen Kanker | PubMed | ||
| 1710166 | WALInnov | PubMed |
Source PubMed
References133
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 8939678 | The retinoblastoma protein pathway and the restriction point. | Curr Opin Cell Biol | 1996 | https://conductscience.org/library/papers/8939678 | PubMed |
| 2 | 22291433 | Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds. | Endocr Relat Cancer | 2012 | https://conductscience.org/library/papers/22291433 | PubMed |
| 3 | 9447971 | Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. | Mol Cell Biol | 1998 | https://conductscience.org/library/papers/9447971 | PubMed |
| 4 | 34568836 | Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders. | Nat Cancer | 2021 | https://conductscience.org/library/papers/34568836 | PubMed |
| 5 | 20609353 | A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. | Cancer Cell | 2010 | https://conductscience.org/library/papers/20609353 | PubMed |
| 6 | 16782892 | Regulated activating Thr172 phosphorylation of cyclin-dependent kinase 4(CDK4): its relationship with cyclins and CDK "inhibitors". | Mol Cell Biol | 2006 | https://conductscience.org/library/papers/16782892 | PubMed |
| 7 | 33941591 | Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation. | Cancer Discov | 2021 | https://conductscience.org/library/papers/33941591 | PubMed |
| 8 | 19237555 | The structure of CDK4/cyclin D3 has implications for models of CDK activation. | Proc Natl Acad Sci U S A | 2009 | https://conductscience.org/library/papers/19237555 | PubMed |
| 9 | 33485464 | First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. | Lancet | 2021 | https://conductscience.org/library/papers/33485464 | PubMed |
| 10 | 16413469 | Requirement for CDK4 kinase function in breast cancer. | Cancer Cell | 2006 | https://conductscience.org/library/papers/16413469 | PubMed |
| 11 | 34544752 | INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors. | Cancer Discov | 2022 | https://conductscience.org/library/papers/34544752 | PubMed |
| 12 | 34592265 | Inhibition of Cyclin Dependent Kinase 4/6 Overcomes Primary Resistance to Programmed Cell Death 1 Blockade in Malignant Mesothelioma. | Ann Thorac Surg | 2022 | https://conductscience.org/library/papers/34592265 | PubMed |
| 13 | 30065701 | Landscape of CDKN1B Mutations in Luminal Breast Cancer and Other Hormone-Driven Human Tumors. | Front Endocrinol (Lausanne) | 2018 | https://conductscience.org/library/papers/30065701 | PubMed |
| 14 | 26719230 | Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. | Lancet | 2016 | https://conductscience.org/library/papers/26719230 | PubMed |
| 15 | 34930610 | Chemotherapy With or Without Bevacizumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma. | J Thorac Oncol | 2022 | https://conductscience.org/library/papers/34930610 | PubMed |
| 16 | 31745297 | Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer. | Oncogene | 2020 | https://conductscience.org/library/papers/31745297 | PubMed |
| 17 | 29590617 | Regulation of Cellular Senescence by Polycomb Chromatin Modifiers through Distinct DNA Damage- and Histone Methylation-Dependent Pathways. | Cell Rep | 2018 | https://conductscience.org/library/papers/29590617 | PubMed |
| 18 | 31174843 | Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy. | Trends Cancer | 2019 | https://conductscience.org/library/papers/31174843 | PubMed |
| 19 | 28003305 | Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma. | Clin Cancer Res | 2017 | https://conductscience.org/library/papers/28003305 | PubMed |
| 20 | 32233024 | Galacto-conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity. | Aging Cell | 2020 | https://conductscience.org/library/papers/32233024 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42842196 | Manganese-Enhanced Magnetic Resonance Imaging: From Translational Research to First-in-Human Trials in Oncology. | Mol Diagn Ther | 2026 | https://conductscience.org/library/papers/42842196 | PubMed |
| 42215475 | CDK4/6 inhibition uncovers subtype-specific vulnerabilities and immune-related responses in esophageal squamous cell carcinoma. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/42215475 | PubMed |
| 41963314 | Pseudo-senescence induced by palbociclib does not sensitise pleural mesothelioma cells to combinations with senolytics. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/41963314 | PubMed |
| 40904706 | Pleural Mesothelioma: Pathogenesis, Diagnosis, Treatment, Prognosis, and Survival. | MedComm (2020) | 2025 | https://conductscience.org/library/papers/40904706 | PubMed |
| 39011477 | Pharmacological inhibition of CDK4/6 impairs diffuse pleural mesothelioma 3D spheroid growth and reduces viability of cisplatin-resistant cells. | Front Oncol | 2024 | https://conductscience.org/library/papers/39011477 | PubMed |
| 37964967 | CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas. | Front Endocrinol (Lausanne) | 2023 | https://conductscience.org/library/papers/37964967 | PubMed |
| 37266562 | CDK4/6 inhibition confers protection of normal gut epithelia against gemcitabine and the active metabolite of irinotecan. | Cell Cycle | 2023 | https://conductscience.org/library/papers/37266562 | PubMed |
| 36765923 | CDK4/6 Inhibitors in Pancreatobiliary Cancers: Opportunities and Challenges. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36765923 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CCNE1 | 898 | PubTator's text mining | https://conductscience.org/library/genes/898 | NCBI Gene |
| CDK4 | 1019 | PubTator's text mining | https://conductscience.org/library/genes/1019 | NCBI Gene |
| CDK6 | 1021 | PubTator's text mining | https://conductscience.org/library/genes/1021 | NCBI Gene |
| CDKN2A | 1029 | PubTator's text mining | https://conductscience.org/library/genes/1029 | NCBI Gene |
| RB1 | 5925 | PubTator's text mining | https://conductscience.org/library/genes/5925 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36453028
GET https://conductscience.org/api/papers/v1/36453028/grants?page=2